CASE REPORT
We report a 46-year-old woman, born in Angola who resided in Portugal since 1999. She had been monitored by the infectious disease department of our hospital since the diagnosis of HIV-1 infection in 2005. At that time she had a blood CD4
1 lymphocyte count of 91 cells/mL and a plasma virus load of 37,369 HIV RNA copies/mL. Highly active antiretroviral therapy (HAART) (zidovudine, lamivudine, and efavirenz) was started. After 4 months, the patient reported the appearance of skin lesions that first developed on her face and subsequently spread caudally. She also reported a burning sensation in hands and feet, nasal obstruction, and mucosal rhinorrhea.
Cutaneous examination revealed a dimorphic eruption. Her face and extremities showed localized areas of multiple 0.5-to 1-cm skin-colored firm papules (60-80 in total). Intermixed with these papules there were nodules and plaques with a bright and smooth surface, slightly darker than normalappearing skin, each approximately 1 to 3 cm in diameter (10-15 in total) (Fig 1, A) . The patient also had supraciliary madarosis, edema localized to both hands and feet, and ichthyosiform scaling of both legs. Many confluent, violaceous-brownish macules with a superficial white fine scale were observed on the soles of the feet (Fig 1, B) . There were no mucosal lesions or palpable lymphadenopathy. Neurologic examination revealed loss of sensation to light touch in some skin lesions, anesthesia of both legs from the feet to the knees, and a thickened painful left ulnar nerve. As a result, the clinical diagnosis of leprosy and Kaposi sarcoma (KS) was suspected.
Skin and mucous bacteriological indices were positive (41, 41) according to Ridley-Jopling classification. Histopathology of a skin biopsy specimen from a plaque on the back of the right hand confirmed the diagnosis: a dense and diffuse inflammatory infiltrate of lymphocytes, histiocytes (some with cytoplasmic vacuolization), and plasmocytes extending from the papillary deeper dermis. With FiteFaraco stain, numerous intracellular and extracellular bacilli were visible. The nerves were also affected by this inflammatory process and by the presence of multiple bacilli. In addition, we observed intermingled spindle-shaped cells forming slitlike spaces, associated with extravascular erythrocytes. Human herpesvirus-8-associated antigens were detected in situ by immunohistochemistry (Fig 2) .
Six months after the onset of HAART the patient's plasma virus load was less than 50 HIV-1 RNA copies/mL and her CD4
1 lymphocyte count had increased to 283 cells/mL. Accordingly, the diagnosis of borderline lepromatous leprosy with reversal (type-1) reaction, associated with KS and presenting as an immune reconstitution inflammatory syndrome (IRIS), was confirmed. The World Health Organizatione recommended multidrug therapy for patients with 
DISCUSSION
The coexistence of multiple entities within a single lesion is not without precedent in patients with HIV-1.
1,2 In fact, leprosy and HIV infection coexist, mainly in Africa, Brazil, and India, and reactional states linked to the introduction of HAART have been recently described in 19 patients with Mycobacterium leprae and HIV coinfection (16 male). [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Since its first report in 2003, it has become clear that the introduction of HAART changed the natural history of leprosy in HIV-infected patients. 3, 15 In 19 cases (including the patient we describe) the clinical manifestations of IRIS were leprosy type-1 reactions, some unusually severe and associated with vasculitis and ulcerous progression. 8 Although it seems that leprosy manifesting as IRIS is similar to leprosy type-1 reactions, in which there is an overaction of T-helper-1 lymphocyte responses to M leprae antigens, it is interesting to notice that the pathomechanisms of both are different. 14, 15 In the former, the primary event is restoration of immunity by HAART, which then recognizes and mounts an immune response against the bacilli. In contrast, in classic type-1 leprosy reactions, there is initial lysis of bacilli by multidrug therapy that then restores the immune system and this reconstituted immune response leads to a type-1 reaction. 11, 16 Furthermore, all reported cases belong to the tuberculoid spectrum of leprosy, implying that there is a good immune host response. This is not true for two patients (including the current one) with borderline lepromatous multibacillary disease; these patients were probably anergic against mycobacteria and as HAART increased cellular immune response, it triggered reactional type-1 leprosy, instead of type-2 reactions. 13 These cases may, therefore, provide indirect evidence that, at least in some patients, the clinical presentation of leprosy is suppressed by HIV-associated advanced immunodeficiency until HAART provides the immunologic ''trigger'' that leads to disease presentation, in all cases within 6 months after the introduction of HAART. 8, 15 An association between KS and HIV infection is also well established. 2 Nevertheless, the association among leprosy, KS, and AIDS has only been reported in 3 patients. 2, 17 The temporal association between the development of skin lesions and changes in blood CD4 1 lymphocyte count and plasma HIV-1 load observed during HAART strongly suggests that the presentation of these two conditions resulted from IRIS. Finally, it is also important to state that if the presentation of these 2 diseases as an IRIS can be detected even in a low leprosy-endemic country such as Portugal, an increase in similar cases can be anticipated in areas where HIV and leprosy occur in higher frequencies, especially as access to HAART becomes more widely available. 
